CDK4 and cancer: It is therefore critical to determine how and why G1‐arrested cells eventually become senescent because this may help to inform ongoing clinical trials assessing CDK4/6 inhibition alongside immunotherapy (currently 14 trials in eight different cancer types (Wagner & Gil, 2020)).